RedHill Biopharma (RDHL) EBITDA Margin (2012 - 2023)
RedHill Biopharma (RDHL) reported EBITDA Margin of 2992.87% for Q2 2023, up 294295.0% year-over-year from N/an in Q2 2022, and up 470.4% quarter-over-quarter from 808.0% in Q1 2023.
RedHill Biopharma (RDHL) EBITDA Margin (2012 - 2023) Analysis & Trends
RedHill Biopharma (RDHL) has 11 years of EBITDA Margin data on file, last reported at 2992.87% in Q2 2023.
- EBITDA Margin for Q2 2023 came in at 2992.87%, up 294295.0% year-over-year; the trailing twelve-month figure through Jun 2023 was 42.99% (up 8198.0% YoY), and the FY2025 annual result was 2776.92%, down 270373.0% from the prior year.
- EBITDA Margin rose to 2992.87% in Q2 2023 per RDHL's latest filing, from 808.0% in the prior quarter.
- Over five years, EBITDA Margin peaked at 2992.87% in Q2 2023 and troughed at 808.0% in Q1 2023.
- A 5-year average of 347.7% and a median of 113.43% in 2021 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2021 and 2023: EBITDA Margin slumped 150024 bps in 2021, then jumped 294295 bps in 2023.
- A 5-year view of EBITDA Margin shows it stood at 739.87% in 2019, then plunged by 88 bps to 91.83% in 2020, then sank by 798 bps to 641.43% in 2021, then advanced by 8 bps to 591.81% in 2022, then soared by 606 bps to 2992.87% in 2023.
- Business Quant data shows RDHL's EBITDA Margin at 2992.87% in Q2 2023, 808.0% in Q1 2023, and 591.81% in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -170.35% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 21.55% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -16.25% |
| 10 | RedHill Biopharma | 142.34 Mn | 142.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 2,992.87% |
| Mar 31, 2023 | -808.00% |
| Dec 31, 2022 | -591.81% |
| Sep 30, 2022 | 203.40% |
| Jun 30, 2022 | 49.92% |
| Mar 31, 2022 | 130.78% |
| Dec 31, 2021 | -641.43% |
| Sep 30, 2021 | 98.97% |
| Jun 30, 2021 | 115.74% |
| Mar 31, 2021 | 111.12% |
| Dec 31, 2020 | 91.83% |
| Sep 30, 2020 | 69.04% |
| Jun 30, 2020 | 59.81% |
| Mar 31, 2020 | 1,611.36% |
| Dec 31, 2019 | 739.87% |
| Sep 30, 2019 | 702.64% |
| Jun 30, 2019 | 792.07% |
| Mar 31, 2019 | 530.40% |
| Dec 31, 2018 | 739.00% |
| Sep 30, 2018 | 441.34% |